CO-ARROW-ELECTRONICS
9.6.2021 16:02:07 CEST | Business Wire | Press release
Global technology solutions provider Arrow Electronics (NYSE:ARW) and ROOQ, an innovator in sports measurement and analytics technology, have teamed up to create the ROOQ BOX, a sensor technology that enables boxers to monitor and review their performance using data that was previously only available under laboratory conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005194/en/
ROOQ BOX comprises a pair of sensors worn within a strap on each wrist. The sensors record the movements made during boxing activity. The data is then analyzed in the accompanying ROOQ app and cloud using machine learning algorithms to provide a precise record of the session. Using this information, boxers and trainers can create a detailed picture of the training session including punch count, punch speeds, variability and punch force. The algorithm has been trained to identify eight different types of punches and to automatically categorize these while filtering out non-boxing specific motions.
The data delivered by the sensor technology, which was inaccessible to athletes until now, provides an invaluable tool to help boxers monitor and improve their performance. This information can be shared with their coaches. In developing the system, ROOQ has drawn on a wide range of experience from within its team including data, software, hardware and firmware specialists, sports scientists and mathematicians as well as boxers and coaches. This experience reaches to the highest level: ROOQ’s chief sports officer, Henry Maske, is an Olympic boxing champion (gold medal, Seoul 1988) and professional world champion (1993 to 1996).
Arrow has been instrumental in leading the project in the firmware and hardware area between the suppliers of components, development and manufacturing services. Also, Arrow’s eInfochips engineering services were utilized in the project. Arrow has used its logistical and supply chain expertise to enable the product to be brought to market, and production scaled, in a smooth and efficient manner.
"This successful collaboration with ROOQ is a perfect example of how expert teams join forces and overcome difficult entrepreneurial challenges together," said Martin Bielesch, president of Arrow’s components business in EMEA. "Arrow's technical and logistical services enabled ROOQ to focus and execute on its leading competencies in delivering a completely new way of capturing diagnostic data in boxing."
Henry Maske sees many advantages in the cooperation between the two companies. "Arrow is a reliable and solution-oriented partner for us. We benefit from their immense experience as well as from their excellent global network.”
Boxing is just the beginning. The training diagnostics technology is universally applicable. Ralf Rüttgers, founder and CEO at ROOQ, is convinced that the application areas of ROOQ are manifold. He said, "Further development and transfer to the fitness market and other related sports, as well as use in the industrial sector, are all possible. Areas such as prevention, safety and health, will play a role in our future training analysis.”
About Arrow Electronics
Arrow Electronics guides innovation forward for over 180,000 leading technology manufacturers and service providers. With 2020 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com .
About ROOQ
ROOQ is about to enter the global market with its training analysis technology. The company employs an interdisciplinary team of over 25 people at its headquarters in Aachen, Germany. The technology model founded in 2018, is a novelty for boxing. For the first time, athletes and coaches receive individualized information on their training performance. For more information, visit rooq.de.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
